Mutual of America Capital Management LLC Sells 21,389 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Mutual of America Capital Management LLC reduced its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 17.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,975 shares of the specialty pharmaceutical company’s stock after selling 21,389 shares during the period. Mutual of America Capital Management LLC’s holdings in Collegium Pharmaceutical were worth $3,077,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Pacer Advisors Inc. lifted its holdings in shares of Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after purchasing an additional 883,380 shares in the last quarter. Natixis Advisors L.P. raised its position in Collegium Pharmaceutical by 152.9% in the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after buying an additional 32,865 shares during the last quarter. Loomis Sayles & Co. L P raised its position in Collegium Pharmaceutical by 32.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after buying an additional 67,439 shares during the last quarter. Barclays PLC raised its position in Collegium Pharmaceutical by 16.9% in the 3rd quarter. Barclays PLC now owns 39,593 shares of the specialty pharmaceutical company’s stock valued at $886,000 after buying an additional 5,713 shares during the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at $286,000.

Collegium Pharmaceutical Trading Down 1.9 %

Shares of Collegium Pharmaceutical stock opened at $34.77 on Friday. Collegium Pharmaceutical, Inc. has a 1 year low of $20.83 and a 1 year high of $40.95. The firm has a market cap of $1.14 billion, a PE ratio of 29.47 and a beta of 1.03. The stock has a fifty day moving average price of $36.82 and a 200-day moving average price of $30.72. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on COLL shares. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 29th. Jefferies Financial Group reissued a “hold” rating and issued a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Piper Sandler reaffirmed an “overweight” rating and set a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Finally, Truist Financial raised their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $39.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.